INSTATAB

Dead / Abandoned — Abandoned — no statement of use filed (as of 03 Jun 2013)

What this means for you

This application is over — abandoned 03 Jun 2013. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
85277030
Mark type
Stylized text
Filed
25 Mar 2011
Published for opposition
04 Sept 2012
Abandoned
03 Jun 2013
Attorney of record
Christopher L. Graff

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of depression; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the immune system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculo-skeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, pain relief medication and anti-inflammatories; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances, namely, medicated skin care preparations for use in dermatology, namely, dermatitis and skin pigmentation diseases; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in ophthalmology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the prevention, treatment and alleviation of circulatory, neurologic, alimentary, auto-immune, pulmonary, musculoskeletal, lymphatic, gastrointestinal, bone sensory, viral, urinary, renal, infectious or metabolic diseases, illnesses, disorders or conditions

Owner

Prosecution history

  • 16 Apr 2025 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
  • 21 Jan 2015 — ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
  • 22 Jan 2014 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
  • 22 Jan 2014 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
  • 03 Jun 2013 — ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
  • 30 Oct 2012 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 04 Sept 2012 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 04 Sept 2012 — PUBLISHED FOR OPPOSITION
  • 15 Aug 2012 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 31 Jul 2012 — LAW OFFICE PUBLICATION REVIEW COMPLETED
  • 31 Jul 2012 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 31 Jul 2012 — EXAMINER'S AMENDMENT ENTERED
  • 30 Jul 2012 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
  • 30 Jul 2012 — EXAMINERS AMENDMENT E-MAILED
  • 30 Jul 2012 — EXAMINERS AMENDMENT -WRITTEN

View this trademark record on Marksy